

BIOSANTE PHARMACEUTICALS INC

Form S-8

October 01, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on October 1, 2002

Registration No. 333-

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

58-2301143

(I.R.S. Employer
Identification No.)

111 Barclay Boulevard, Suite 280

Lincolnshire, Illinois

(Address of Principal Executive Offices)

60069

(Zip Code)

AMENDED AND RESTATED 1998 STOCK OPTION PLAN

(Full title of the plan)

Phillip B. Donenberg

Chief Financial Officer

BioSante Pharmaceuticals, Inc.

111 Barclay Boulevard, Suite 280

Lincolnshire, IL 60069

(847) 478-0500

(Name, address and telephone number,
including area code, of agent for service)

Approximate date of commencement of proposed sale to the public:

Immediately upon the filing of this registration statement

CALCULATION OF REGISTRATION FEE

Title of securities to be registered	Amount to be registered(1)	Proposed maximum offering price per unit(2)	Proposed maximum aggregate offering price	Amount of registration fee(2)
Common Stock, par value \$0.0001 per share	300,000	\$1,230,000	\$4.10	\$114.00(3)

- (1) Represents the increase in the total number of shares reserved for issuance under the registrant's Amended and Restated 1998 Stock Option Plan. An aggregate of 700,000 shares has been previously registered under a registration statement on Form S-8 (File No. 333-53384) In addition, pursuant to Rule 416 under the Securities Act of 1933, this registration statement includes an indeterminate number of additional shares that may be offered and sold as a result of anti-dilution provisions described in the registrant's Amended and Restated 1998 Stock Option Plan.
- (2) Estimated solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule 457(h) under the Securities Act as follows: (i) with respect to options to purchase shares previously granted under the Amended and Restated 1998 Stock Option Plan, on the basis of the weighted average exercise price of these options, and (ii) with respect to options to be granted under the plan based on the average between the high and low sales prices of the registrant's common stock on September 27, 2002 on the over-the-counter market, as reported by the Over-the-Counter Bulletin Board.
- (3) BioSante filed a registration statement on Form SB-2 (File No. 333-87542) on May 3, 2002 which was declared effective on August 27, 2002. The SEC filing fee previously paid in connection with the Form SB-2 was \$920.00. Before that offering under the Form SB-2 was terminated pursuant to a post-effective amendment that was declared effective on September 12, 2002, BioSante sold shares at an aggregate purchase price of \$4,500,000 for an SEC filing fee of \$414.00. Pursuant to Rule 457(p), BioSante is offsetting the \$120.00 filing fee due in connection with this registration statement against the remaining \$506.00 of the filing fee from the terminated offering.
-
-
-

**STATEMENT UNDER GENERAL INSTRUCTION E
REGISTRATION OF ADDITIONAL SECURITIES**

The registrant, BioSante Pharmaceuticals, Inc., previously filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC File No. 333-53384) in connection with the registration of an aggregate of 700,000 (as adjusted to reflect a 1-for-10 reverse stock split effective on May 31, 2002) shares of BioSante's common stock to be issued under BioSante's Amended and Restated 1998 Stock Option Plan. BioSante amended this previous registration statement by virtue of a post-effective amendment No. 1 pursuant to Rule 414 under the Securities Act of 1933, as amended, to reflect the reincorporation of BioSante from the State of Wyoming to the State of Delaware.

Pursuant to General Instruction E of Form S-8, this registration statement is filed by BioSante solely to register an additional 300,000 (as adjusted to reflect a 1-for-10 reverse stock split effective on May 31, 2002) shares of common stock reserved for issuance under BioSante's Amended and Restated 1998 Stock Option Plan. These increases were approved by BioSante's board of directors and stockholders. Pursuant to Instruction E, the contents of BioSante's previously filed registration statement on Form S-8 (SEC File No. 333-53384) and the post-effective amendment No. 1 thereto, including without limitation periodic reports that BioSante filed, or will file, after this registration statement to maintain current information about BioSante, are hereby incorporated by reference into this registration statement pursuant to General Instruction E of Form S-8.

Part II
**INFORMATION REQUIRED
IN THE REGISTRATION STATEMENT**

Item 8. Exhibits.

**Exhibit
No.**

Description

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form S-8

<u>Signature</u>	<u>Title</u>
Louis W. Sullivan, M.D.	
<u>/s/ VICTOR MORGENSTERN</u>	Director
Victor Morgenstern	
<u>/s/ EDWARD C. ROSENOW, III, M.D.</u>	Director
Edward C. Rosenow, III, M.D.	
<u>/s/ FRED HOLUBOW</u>	Director
Fred Holubow	
<u>/s/ ROSS MANGANO</u>	Director
Ross Mangano	
<u>/s/ ANGELA HO</u>	Director
Angela Ho	
<u>/s/ PETER KJAER</u>	Director
Peter Kjaer	

3

**BIOSANTE PHARMACEUTICALS, INC.
REGISTRATION STATEMENT ON FORM S-8**

INDEX TO EXHIBITS

<u>Exhibit No.</u>	<u>Item</u>	<u>Method of Filing</u>
5.1	Opinion of Oppenheimer Wolff & Donnelly LLP	Filed herewith.
23.1	Consent of Deloitte & Touche LLP	Filed herewith.
23.2	Consent of Oppenheimer Wolff & Donnelly LLP	Included in Exhibit 5.1.
24.1	Power of Attorney	Included on the signature page to this registration statement.

QuickLinks

STATEMENT UNDER GENERAL INSTRUCTION E REGISTRATION OF ADDITIONAL SECURITIES
Part II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

SIGNATURES

POWER OF ATTORNEY

